The higher percentages of both CD4 and CD8 T cells in spleen and blood suggest that mice treated with NBTXR3  +  HDXRT  +  LDXRT  +  ICIs maintained a long-term adaptive immune response against tumor, which could be responsible for eradicating the re-injected cancer cells. Here, CD8A is linked to cancer.